Professor, Pathology, University of Miami School of Medicine
Urology
Dr. Norman L. Block, MD
|
|
Give Review
Doctor Norman L. Block, MD is an expert in the field of Urology. He went to medical school at NYU School of Medicine. He has 2 awards "Super Doctor" and "Fellow (FACS)". Norman Block is a published doctor. He published 100 publications, including: 'Potential application of a chemically modified non-antimicrobial tetracycline (CMT-3) against metastatic prostate cancer.'
Publications
- GHRH Receptor Expression in Malignant Mixed Müllerian Tumors: A Potentially Targetable Biopredictor.
- Role of growth hormone-releasing hormone in dyslipidemia associated with experimental type 1 diabetes.
- Beneficial effects of growth hormone-releasing hormone agonists on rat INS-1 cells and on streptozotocin-induced NOD/SCID mice.
- Potentiating effects of GHRH analogs on the response to chemotherapy.
- Expression of Receptors for Pituitary-Type Growth Hormone-Releasing Hormone (pGHRH-R) in Human Papillary Thyroid Cancer Cells: Effects of GHRH Antagonists on Matrix Me...
- Novel GHRH antagonists suppress the growth of human malignant melanoma by restoring nuclear p27 function.
- Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant Prostate cancer ...
- Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human Prostate cancer.
- Synthesis of new potent agonistic analogs of growth hormone-releasing hormone (GHRH) and evaluation of their endocrine and cardiac activities.
- Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonists.
- Agonists of luteinizing hormone-releasing hormone in Prostate cancer.
- Mini-review: novel therapeutic strategies to blunt actions of pneumolysin in the lungs.
- Re: Editorial Comment on LHRH Antagonist Cetrorelix Reduces Prostate Size and Gene Expression of Proinflammatory Cytokines and Growth Factors in a Rat Model of Benign ...
- Suppression of the proliferation of human U-87 MG glioblastoma cells by new antagonists of growth hormone-releasing hormone in vivo and in vitro.
- Shrinkage of experimental benign prostatic hyperplasia and reduction of prostatic cell volume by a gastrin-releasing peptide antagonist.
- Hormonal manipulation of benign prostatic hyperplasia.
- Mechanisms of synergism between antagonists of growth hormone-releasing hormone and antagonists of luteinizing hormone-releasing hormone in shrinking experimental beni...
- GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon Cancer.
- Beneficial effects of novel antagonists of GHRH in different models of Alzheimer's disease.
- Powerful inhibition of in-vivo growth of experimental hepatic Cancers by bombesin/gastrin-releasing peptide antagonist RC-3940-II.
- Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon Cancers.
- Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage.
- Activation of growth hormone releasing hormone (GHRH) receptor stimulates cardiac reverse remodeling after myocardial infarction (MI).
- Modulation of pancreatic islets-stress axis by hypothalamic releasing hormones and 11{beta}-hydroxysteroid dehydrogenase.
- Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian Cancers.
- Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetror...
- Antagonists of growth hormone-releasing hormone (GHRH) reduce Prostate size in experimental benign prostatic hyperplasia.
- GHRH and wound healing.
- Acceleration of wound healing by growth hormone-releasing hormone and its agonists.
- LHRH antagonist Cetrorelix reduces Prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.
- Agonist of growth hormone-releasing hormone as a potential effector for survival and proliferation of pancreatic islets.
- Antagonists of growth hormone-releasing hormone inhibit the proliferation of human benign prostatic hyperplasia cells.
- Cardioprotective effects of growth hormone-releasing hormone agonist after myocardial infarction.
- Civilian gunshot injuries of the penis: the Miami experience.
- Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic Prostate cancer model.
- A rare case of renal gastrinoma.
- Expression of mRNA for human type-I LHRH receptor transcript forms in human benign prostatic hyperplasia.
- Activation of mitogen-activated protein kinases by a splice variant of GHRH receptor.
- Potential application of a chemically modified non-antimicrobial tetracycline (CMT-3) against metastatic Prostate cancer.
- Inhibition of aromatase activity and growth suppression by 4-methoxy-4-androstene-3,17-dione in an androgen sensitive human prostatic carcinoma cell line.
- CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of Prostate cancer.
- Inhibition of Prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089.
- Enhancement of hyperthermic toxicity by lonidamine in the Dunning R3327G rat prostatic adenocarcinoma.
- Modulation of aromatase activity by growth factors in an androgen sensitive human Prostate cancer cell line, LNCaP.
- Stromal and epithelial expression of tumor markers hyaluronic acid and HYAL1 hyaluronidase in Prostate cancer.
- Human prostatic inhibin suppresses tumor growth and inhibits clonogenic cell survival of a model prostatic adenocarcinoma, the Dunning R3327G rat tumor.
- Isolation of a Prostate carcinoma cell proliferation-inhibiting factor from human seminal plasma and its similarity to transforming growth factor beta.
- Enhancement of radiation response of prostatic carcinoma by taxol: therapeutic potential for late-stage malignancy.
- Expression of CD44 in Prostate cancer cells: association with cell proliferation and invasive potential.
- Detection of prostatic-inhibin-like peptide in the cytoplasm of LNCaP cells, a human prostatic adenocarcinoma cell line.
- Interaction between stromal cells and tumor cells induces chemoresistance and matrix metalloproteinase secretion.
- Enhancement of radiation response of prostatic carcinoma by lonidamine.
- Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human Prostate in explant cultures: reduced tissue inhibitor of...
- Expression of prostatic TRH-like peptides differs between species and between malignant and nonmalignant tissues.
- Her2 expression in prostatic Cancer: a comparison with mammary carcinoma.
- Maximal androgen blockade for patients with metastatic Prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with lutein...
- A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostat...
- Conservative surgical treatment of renal cell carcinoma. The University of Miami experience.
- Exploratory analysis on the effect of race on clinical outcome in patients with advanced Prostate cancer receiving bicalutamide or flutamide, each in combination with ...
- Metastatic Prostate cancer presenting as obstructive jaundice.
- Interaction of irradiation and microwave-induced hyperthermia in the Dunning R3327G prostatic adenocarcinoma model.
- Secretion of bladder tumor-derived hyaluronidase activity by invasive bladder tumor cells.
- Methodology for preservation of high molecular-weight RNA in paraffin-embedded tissue: application for laser-capture microdissection.
- Association of elevated levels of hyaluronidase, a matrix-degrading enzyme, with Prostate cancer progression.
- Malignant fibrous histiocytoma of spermatic cord.
- Effects of the gonadotropin-releasing hormone agonist [D-leu6, desgly-NH2(10), proethylamide9]-GnRH (leuprolide) on R3327-G rat prostatic tumor growth.
- Investigation of different combinations of estrogen therapy and radiation therapy on prostatic adenocarcinoma (R-3327).
- Identification of the human seminal TRH-like peptide pGlu-Phe-Pro-NH2 in normal human Prostate.
- Renal parenchyma-sparing surgery as conservative treatment of renal cell carcinoma.
- Systematic investigation into interaction of ionizing radiation and doxorubicin in the Dunning R3327G prostatic adenocarcinoma model.
- Radical Prostatectomy: is complete resection of the seminal vesicles really necessary?
- Hormone sensitivity of the R3327-G rat Prostate adenocarcinoma: growth rate, DNA content, and hormone receptors.
- Flow-cytometric DNA analysis of paraffin-embedded renal cell carcinoma tissue from patients treated by parenchymal-sparing surgery.
- Control of growth, morphology, and alkaline phosphatase activity by butyrate and related short-chain fatty acids in the retinoid-responsive 9-1C rat prostatic adenocar...
- Zoladex versus orchiectomy in treatment of advanced Prostate cancer: a randomized trial. Zoladex Prostate Study Group.
- Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind,...
- Comparison of goserelin and leuprolide in combined androgen blockade therapy.
- Inhibition of growth and guanylate cyclase activity of an undifferentiated Prostate adenocarcinoma by an extract of the balsam pear (Momordica charantia abbreviata).
- Carcinoma of urinary tract. Clinical significance of urinary phosphokinase activity in diagnosis.
- Tumor progression in serial passages of the Dunning R3327-G rat prostatic adenocarcinoma: growth rate response to endocrine manipulation.
- Effect of retinoic acid on the growth and morphology of a prostatic adenocarcinoma cell line cloned for the retinoid inducibility of alkaline phosphatase.
- In vivo selection of androgen-insensitive cells in R3327-G rat Prostate tumors: diethylstilbestrol diphosphate treatment versus orchiectomy.
- Small cell carcinoma of the Prostate gland with inappropriate antidiuretic hormone secretion: morphological, immunohistochemical and clinical expressions.
- A new self-expanding lined stent-graft in the dog ureter: radiological, gross, histopathological and scanning electron microscopic findings.
- A renal protocol for all ages and all indications: mercapto-acetyl-triglycine (MAG3) with simultaneous injection of furosemide (MAG3-F0): a 17-year experience.
- Measurement of cell-cycle phase-specific cell death using Hoechst 33342 and propidium iodide: preservation by ethanol fixation.
- Tumor-associated hyaluronic acid: a new sensitive and specific urine marker for bladder Cancer.
- Tumor-derived hyaluronidase: a diagnostic urine marker for high-grade bladder Cancer.
- Leiomyoma of the epididymis.
- Flow cytometric analysis of DNA and nuclear protein in paraffin-embedded tissue.
- Small bowel perforation associated with intraperitoneal and extraperitoneal bladder perforation caused by stab wound to the penis.
- Chemotherapy of the transplantable adenocarcinoma (R-3327) of the Copenhagen rat.
- Flow cytometric analysis of R3327 rat Prostate adenocarcinoma grown in vivo and in vitro.
- Flow cytometric monitoring of R 3327 rat Prostate carcinoma.
- Urinary hyaluronic acid and hyaluronidase: markers for bladder Cancer detection and evaluation of grade.
- HA-HAase urine test. A sensitive and specific method for detecting bladder Cancer and evaluating its grade.
- DNA patterns in parathyroid disease predict postoperative parathyroid hormone secretion.
- Aneuploidy of glandular epithelial cells in histologically normal Prostate glands.
- Single-agent therapy with bicalutamide: a comparison with medical or surgical castration in the treatment of advanced Prostate carcinoma.
Schools
New York University School Of Medicine
Baylor University Med Center
New York University
Meml Sloan Kettering Canc Center
Conditions Treated
- Prostate Cancer
Doctors Specialties
- Urology
Accepted Insurances
Awards
- Super Doctor
- Fellow (FACS)
Education
-
Memorial Sloan-Kettering Cancer Center -
NYU School of Medicine -
Baylor University Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Guarionex R. De Castro, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Raymond J. Leveillee, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Keith F. Russell, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James D. Daughtry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ian Nisonson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ramgopal Satyanarayana Konanur, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carlos A. Nazir, MD |
|
|
Dr. Jorge Caso, MD |
|
Dr. Rafael Antun, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Devendar Katkoori, MD |
|
|
Dr. Amanda L. Mure, MD |
|
|
Dr. Eran Rosenberg, MD
This Doctor is OpenDoctor Recommended.
|